{"id":"https://openalex.org/W2586579566","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps668","title":"A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.","display_name":"A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.","publication_year":2014,"publication_date":"2014-05-20","ids":{"openalex":"https://openalex.org/W2586579566","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps668","mag":"2586579566"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2014.32.15_suppl.tps668","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps668","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps668","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080530218","display_name":"Rachel A. Freedman","orcid":"https://orcid.org/0000-0003-0460-674X","observed_orcids":["https://orcid.org/0000-0003-0460-674X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel A. Freedman","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103783700","display_name":"In\u00eas Maria Vaz Duarte Luis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ines Maria Vaz Duarte Luis","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112035683","display_name":"William Thomas Barry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Thomas Barry","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032785430","display_name":"Ian E. Krop","orcid":"https://orcid.org/0000-0002-6380-5944","observed_orcids":["https://orcid.org/0000-0002-6380-5944"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian E. Krop","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068721624","display_name":"Nikhil Wagle","orcid":"https://orcid.org/0000-0003-3332-9438","observed_orcids":["https://orcid.org/0000-0003-3332-9438"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nikhil Wagle","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031720297","display_name":"Alarice Cheng-Yi Lowe","orcid":"https://orcid.org/0000-0002-3235-9013","observed_orcids":["https://orcid.org/0000-0002-3235-9013"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alarice Lowe","raw_affiliation_strings":["Brigham and Women's Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham and Women's Hospital, Boston, MA","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043756881","display_name":"Sarah R Galler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Galler","raw_affiliation_strings":["Dana-Farber Cancer Center Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Center Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040999127","display_name":"Jessica J. Sohl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica Sohl","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057580348","display_name":"Steven Jay Isakoff","orcid":"https://orcid.org/0000-0002-6677-1014","observed_orcids":["https://orcid.org/0000-0002-6677-1014"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven J. Isakoff","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051532432","display_name":"Nadine Tung","orcid":"https://orcid.org/0000-0003-1422-3734","observed_orcids":["https://orcid.org/0000-0003-1422-3734"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nadine M. Tung","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Boston, MA","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070245248","display_name":"Eric P. Winer","orcid":"https://orcid.org/0000-0002-8819-1723","observed_orcids":["https://orcid.org/0000-0002-8819-1723"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric P. Winer","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022319770","display_name":"NU Lin","orcid":"https://orcid.org/0000-0003-2263-5413","observed_orcids":["https://orcid.org/0000-0003-2263-5413"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nancy U. Lin","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"32","issue":"15_suppl","first_page":"TPS668","last_page":"TPS668"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.011599999852478504,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/eribulin-mesylate","display_name":"eribulin mesylate","score":0.9909999966621399},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":1.0},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9879999756813049},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.7919999957084656},{"id":"https://openalex.org/keywords/circulating-tumor-cells","display_name":"circulating tumor cells","score":0.8619999885559082},{"id":"https://openalex.org/keywords/copy-number-variation","display_name":"copy number variation","score":0.8529999852180481},{"id":"https://openalex.org/keywords/tumor-mutational-profile","display_name":"tumor mutational profile","score":0.7490000128746033},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8830000162124634},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8090000152587891},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9539999961853027},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.5630000233650208}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9192103147506714},{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.9169467091560364},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.8575066924095154},{"id":"https://openalex.org/C2776387010","wikidata":"https://www.wikidata.org/wiki/Q408717","display_name":"Eribulin","level":5,"score":0.8418914079666138},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.7788516283035278},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.685692548751831},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6810076832771301},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6755788326263428},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4645058810710907},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.414937287569046},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4072887599468231},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.35354262590408325},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3236311674118042},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2761850655078888}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2014.32.15_suppl.tps668","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps668","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps668","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8399999737739563}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2621905180","https://openalex.org/W2791078611","https://openalex.org/W1881338314","https://openalex.org/W4379283868","https://openalex.org/W2624170378","https://openalex.org/W3080117833","https://openalex.org/W4200280246","https://openalex.org/W2890213442","https://openalex.org/W2258822133","https://openalex.org/W4236276668"],"abstract_inverted_index":{"TPS668":[0],"Background:":[1],"As":[2],"a":[3,88,104,125,223,281,300],"single":[4,89],"agent,":[5],"eribulin":[6,62,117],"is":[7,87,153,222,280,297,316,338],"associated":[8],"with":[9,21,65,71],"prolonged":[10],"overall":[11,36,169],"survival":[12,37,170],"compared":[13],"to":[14,40,96,182,248],"treatment":[15],"of":[16,61,82,99,116,124,178,193,213,276,284,289,303,308],"physician\u2019s":[17],"choice":[18],"in":[19,49,63,69,190,200,206,331],"pts":[20,70,219,233,255],"heavily":[22],"pre-treated":[23],"metastatic":[24,133,203],"breast":[25],"cancer":[26],"(MBC).":[27],"In":[28,228],"the":[29,50,59,97,100,229,244,249,267,270,286,293,305,312],"first-line":[30],"setting,":[31],"pertuzumab":[32,68],"improves":[33],"progression-free":[34],"and":[35,42,67,109,137,168,173,175,180,187,196,205,211,218,299],"when":[38],"added":[39],"trastuzumab":[41,66],"chemotherapy;":[43],"however":[44],"there":[45,238,260],"are":[46,239,261],"limited":[47],"data":[48],"second":[51,250],"line":[52,81],"or":[53],"beyond.":[54],"This":[55,86,221],"study":[56,245,291,310],"will":[57,130,146,234,246,256,272],"evaluate":[58],"efficacy":[60],"combination":[64],"HER2+":[72],"MBC":[73],"who":[74],"have":[75],"progressed":[76],"after":[77],"at":[78,135,140,240,262],"least":[79,241,263],"1":[80],"trastuzumab-based":[83],"therapy.":[84],"Methods:":[85],"center,":[90],"single-arm,":[91],"phase":[92,101,326],"II":[93,102,327],"study.":[94,278],"Prior":[95],"start":[98],"study,":[103],"safety":[105,172],"run-in":[106],"was":[107,118],"conducted":[108],"enrolled":[110],"6":[111],"patients.":[112],"The":[113,150,325,334],"established":[114],"dose":[115],"1.4mg/m2":[119],"on":[120],"days":[121],"1,":[122],"8":[123],"21":[126],"day":[127],"cycle.":[128],"Pts":[129],"undergo":[131],"mandatory":[132],"biopsies":[134,139],"baseline":[136],"optional":[138],"progression.":[141],"Circulating":[142],"tumor":[143,216],"cells":[144],"(CTC)":[145],"also":[147],"be":[148,235,257,273],"collected.":[149],"primary":[151,201],"aim":[152],"objective":[154],"response":[155,179,295,314],"rate,":[156,165],"RECIST":[157],"1.1.":[158],"Secondary":[159],"aims":[160],"include:":[161],"(a)":[162],"Clinical":[163,341],"benefit":[164],"progression":[166],"free":[167],"(b)":[171],"tolerability,":[174],"(c)":[176],"mechanisms":[177],"resistance":[181],"HER2-directed":[183],"therapy,":[184],"including":[185],"MET":[186],"HER2":[188],"co-amplification":[189],"CTCs,":[191],"comparisons":[192],"mutational":[194],"profiles":[195],"copy":[197],"number":[198],"variation":[199],"vs.":[202,208],"tumors":[204],"pre-treatment":[207],"resistant":[209],"tumors,":[210],"exploration":[212],"correlations":[214],"between":[215],"characteristics":[217],"outcomes.":[220],"two-stage":[224],"Simon":[225],"Minimax":[226],"design.":[227],"first":[230],"stage,":[231],"34":[232],"entered.":[236,258],"If":[237,259],"9":[242],"responses,":[243],"continue":[247],"stage":[251],"where":[252],"another":[253],"22":[254],"18":[264],"responses":[265],"among":[266],"56":[268],"pts,":[269],"regimen":[271,287,306],"declared":[274],"worthy":[275,288,307],"further":[277,290,309],"There":[279],"90%":[282],"chance":[283,302],"declaring":[285,304],"if":[292,311],"true":[294,313],"rate":[296,315,337],"40%":[298],"10%":[301,320],"24%":[317],"(90%":[318],"power,":[319],"Type":[321],"I":[322],"error":[323],"rate).":[324],"portion":[328],"began":[329],"enrollment":[330],"January":[332],"2014.":[333],"estimated":[335],"accrual":[336],"3-5":[339],"patients/month.":[340],"trial":[342],"information:":[343],"NCT01912963.":[344]},"counts_by_year":[{"year":2016,"cited_by_count":1}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2017-02-17T00:00:00"}